RxDoctor Payments Data

Sterling Smith

Acute Care · Seguin, TXNPI 1134733652

Payments from drug & device makers

$2,323in general payments, 2019–2025

Across 105 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$659
  • Boston Scientific$620
  • Esperion Therapeutics, Inc.$168
  • Novartis$160
  • Merck$133
  • Endologix LLC$128
  • plus $455 from 14 others

What the payments were for

  • Food & beverage$2,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,323 in reported general payments places this provider in the 85th percentile of 2,323 acute care providers in Texas.

See all acute care providers in Texas

Medicare billing

Part B allowed, 2024
$116,355
Medicare patients
732
Services billed
2,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$128,240
XareltoRivaroxaban67$60,210
JardianceEmpagliflozin26$18,127
Carvedilol ErCarvedilol Phosphate12$1,598
Carvedilol177$1,454
Valsartan67$1,445
Metoprolol Succinate99$1,217
Diltiazem 24hr Er (Cd)Diltiazem Hcl34$1,162
Nifedipine ErNifedipine39$611
Atorvastatin Calcium90$588
ClopidogrelClopidogrel Bisulfate36$585
Losartan Potassium66$544
Furosemide102$409
Flecainide Acetate12$392
Amlodipine Besylate78$370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$128,240160 claims
Johnson & JohnsonXarelto$659$60,21067 claims
Boehringer IngelheimJardiance$49$18,12726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,323 acute care providers in Texas.

Other acute care in Seguin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →